Nebenwirkungsmanagement in der Immunonkologie

Abstract

The previous articles have addressed various indications for systemic therapy of head and neck cancer. Furthermore, useful considerations pertinent to establishing an outpatient treatment facility have been discussed. A very high proportion of immunotherapeutic agents are employed in an outpatient treatment facility, including nivolumab, pembrolizumab, and cemiplimab. Although these agents are far better tolerated than classical chemotherapeutic drugs, they can also cause severe adverse events. How these can be recognized and treated is the subject of the current article.